Sandoz in the Media
Navigate within 'Sandoz in the Media'
- Page
- 1
- 2
BioForum: Biosimilars - Pioneering the Future
March 08, 2012
On 24th May 2012 in Brno, Czech Republic, during BioForum, one of the keynote speakers - Dr. Steffen Wagner, Head Commercial Operations Central & Eastern Europe at Sandoz – will present a talk: “Biosimilars – Pioneering the Future”. Dr. Wagner, formerly Director Global Strategic Planning at Sandoz
and Engagement Manager with McKinsey and Company’s Pharmaceutical Industry Practice, will discuss the development process, key challenges, regulatory environment, requirements for successful commercialization and key success factors for companies in the field.
Mark McCamish Presents Sandoz perspective on FDA biosimilar guidelines on BioCentury TV
February 23, 2012
Mark McCamish, Head of Global Biopharmaceutical Development at Sandoz, was invited by BioCentury TV to present the industry perspective on the FDA’s new biosimilar guidance document.
Enoxaparin gives Sandoz injectables lead
Generics Bulletin, p.5, February 03, 2012
Sandoz claims it is now the world’s leading supplier of generic injectables after 2011 sales of its US rival to Sanofi’s Lovenox (enoxaparin) narrowly exceeded annual sales of US$1.0 billion. Retail sales of the firm’s anti-infective injectables rose by a tenth last year, while it also benefitted from the roster of oncology drugs acquired by paying US$1.3 billion for Austria’s Ebewe Pharma in September 2009.
Hexal moves into tenders
Generics Bulletin, p.23, February 03, 2012
When Germany’s AOK group of statutory health insurance funds announced the results of its seventh round of tender contracts in late- November last year, Sandoz grabbed the headlines for more than one reason. Novartis’ generics business led the way by capturing 145 of the 737 regional supply contracts awarded, ahead of Stada in second place on 127 contracts and Teva in third with 118 of the contracts handed out by the fund, which accounts for just over a third of Germany’s statutory health insurance market.
Fortune's 40 under 40: Jeff George ranked number nine.
October 21, 2011
They're the hottest young stars in business across the globe. They're innovators, disrupters, and job creators; in fact, it's a pretty safe bet you're going to be working for them someday -- if you aren't already! They're in technology, yes, but also in movies, music, athletic wear, and even curry-flavored chocolate. And the scary thing is they're just getting started
Sandoz strikes Japanese licensing deal with Nipro
Generics Bulletin, p.01, July 15, 2011
Sandoz will license and co-develop products for the Japanese market with Nipro Corporation as part of a strategic alliance between the two companies. Having worked with Nipro on “various product licensing deals” since 2007, Sandoz said the
latest agreement expanded areas of co-operation between the two companies to include
cross-licesing existing portfolios and co-developing future products across a number of therapeutic areas. The “first wave” of cross-licensed products would be launched within “the next several months”, Sandoz added.
Sandoz' enoxaparin share nears 50%
Generics Bulletin, p.05, May 06, 2011
Winning new customers for its rival to Sanofi-Aventis’ Lovenox (enoxaparin) lifted Sandoz’ share of the US market for the anticoagulant to almost 50% in the first quarter of this year, according to Jeff George, global head of Novartis’ generics division.
Sandoz aims at asthma by signing deal for Oriel
Generics Bulletin, p.01, April 23, 2011
Sandoz has strengthened its position in the respiratory generics market by signing a definitive agreement to acquire privately-held US company Oriel Therapeutics for an undisclosed fee. The deal for Oriel will give Sandoz “three promising development projects” targeting leading brands for asthma and chronic obstructive pulmonary disease (COPD), as well as the FreePath drug-delivery system and Solis multi-dose dry-powder inhalers.
Worldwide experience with biosimilar development
mAbs 3:2, pp.212-220; March/April 2011;
Mark McCamish, Sandoz's Head of Global Biopharmaceutical Development, co-authored a peer-reviewed article on the importance of biosimilar development.
Enoxaparin makes a difference for Sandoz
Generics Bulletin, p.9, February 01, 2011
AUS$462 million contribution from the generic version of Sanofi-Aventis’ Lovenox (enoxaparin) blockbuster that Sandoz launched last July in the US helped to lift the proportion of Sandoz’ US$8.52 billion turnover last year that the firm derived from ‘differentiated’ products by 10 percentage points to 42%, or around US$3.6 billion.
Navigate within 'Sandoz in the Media'
- Page
- 1
- 2
